These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 25678084)

  • 1. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
    Rao Z; Dang ZL; Li B; Zhu L; Qin HY; Wu XA; Wei YH
    Ther Drug Monit; 2020 Aug; 42(4):578-587. PubMed ID: 32049891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases.
    Park MK; Lim KS; Kim TE; Han HK; Yi SJ; Shin KH; Cho JY; Shin SG; Jang IJ; Yu KS
    Ther Drug Monit; 2012 Oct; 34(5):599-603. PubMed ID: 22929406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
    Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR
    Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL; Smith JW; Geckler RW; Wilson SE
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcome and Antimicrobial Therapeutic Drug Monitoring for the Treatment of Infections in Acute Burn Patients.
    Machado AS; Oliveira MS; Sanches C; Silva Junior CVD; Gomez DS; Gemperli R; Santos SRCJ; Levin AS
    Clin Ther; 2017 Aug; 39(8):1649-1657.e3. PubMed ID: 28705450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation on administration method of carbapenems].
    Mikamo H; Ninomiya M; Tamaya T
    Jpn J Antibiot; 2002 Dec; 55(6):875-81. PubMed ID: 12621741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP; Goudie J; Nishiki K; Williams PD
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.